User login
Key clinical point: Children with atopic dermatitis (AD) have an increased risk for multiple comorbidities, even beyond atopic disorders, with a positive association between AD severity and the risk for comorbidity onset.
Major finding: In children with vs without AD, the risk for hypersensitivity and allergic disorders was the highest (hazard ratio [HR] 3.87; 95% CI 3.77-3.97), followed by that for malignancies (HR 2.53; 95% CI 1.96-3.26) and immunological and inflammatory disorders (HR 2.36; 95% CI 2.22-2.50). Hypersensitivity onset risk increased in children with mild-to-moderate (adjusted HR 2.71; 95% CI 2.41-3.05) and severe (adjusted HR 3.56; 95% CI 3.10-4.09) AD compared with those in remission.
Study details: This observational, retrospective cohort study included 165,145 children with AD (age < 18 years) who were matched with 165,145 children without AD.
Disclosures: This study was sponsored by Pfizer Inc. Some authors declared receiving research grants or consultancy fees from or serving as advisors, investigators, etc., for Pfizer and others. Six authors declared being employees of or holding stock or stock options in Pfizer.
Source: von Kobyletzki L et al. Comorbidities in childhood atopic dermatitis: A population-based study. J Eur Acad Dermatol Venereol. 2023 (Oct 12). doi: 10.1111/jdv.19569
Key clinical point: Children with atopic dermatitis (AD) have an increased risk for multiple comorbidities, even beyond atopic disorders, with a positive association between AD severity and the risk for comorbidity onset.
Major finding: In children with vs without AD, the risk for hypersensitivity and allergic disorders was the highest (hazard ratio [HR] 3.87; 95% CI 3.77-3.97), followed by that for malignancies (HR 2.53; 95% CI 1.96-3.26) and immunological and inflammatory disorders (HR 2.36; 95% CI 2.22-2.50). Hypersensitivity onset risk increased in children with mild-to-moderate (adjusted HR 2.71; 95% CI 2.41-3.05) and severe (adjusted HR 3.56; 95% CI 3.10-4.09) AD compared with those in remission.
Study details: This observational, retrospective cohort study included 165,145 children with AD (age < 18 years) who were matched with 165,145 children without AD.
Disclosures: This study was sponsored by Pfizer Inc. Some authors declared receiving research grants or consultancy fees from or serving as advisors, investigators, etc., for Pfizer and others. Six authors declared being employees of or holding stock or stock options in Pfizer.
Source: von Kobyletzki L et al. Comorbidities in childhood atopic dermatitis: A population-based study. J Eur Acad Dermatol Venereol. 2023 (Oct 12). doi: 10.1111/jdv.19569
Key clinical point: Children with atopic dermatitis (AD) have an increased risk for multiple comorbidities, even beyond atopic disorders, with a positive association between AD severity and the risk for comorbidity onset.
Major finding: In children with vs without AD, the risk for hypersensitivity and allergic disorders was the highest (hazard ratio [HR] 3.87; 95% CI 3.77-3.97), followed by that for malignancies (HR 2.53; 95% CI 1.96-3.26) and immunological and inflammatory disorders (HR 2.36; 95% CI 2.22-2.50). Hypersensitivity onset risk increased in children with mild-to-moderate (adjusted HR 2.71; 95% CI 2.41-3.05) and severe (adjusted HR 3.56; 95% CI 3.10-4.09) AD compared with those in remission.
Study details: This observational, retrospective cohort study included 165,145 children with AD (age < 18 years) who were matched with 165,145 children without AD.
Disclosures: This study was sponsored by Pfizer Inc. Some authors declared receiving research grants or consultancy fees from or serving as advisors, investigators, etc., for Pfizer and others. Six authors declared being employees of or holding stock or stock options in Pfizer.
Source: von Kobyletzki L et al. Comorbidities in childhood atopic dermatitis: A population-based study. J Eur Acad Dermatol Venereol. 2023 (Oct 12). doi: 10.1111/jdv.19569